Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 7/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20208533 | 0.86 | SCN5A (0.55) | CYP1A2SCN5AMKNK1MKNK2TNF | |
| SCHEMBL20203933 | 0.83 | CYP1A2 (0.64) | CYP1A2SCN5A | |
| SCHEMBL20188612 | 0.82 | CYP1A2 (0.42) | CYP1A2MKNK1MKNK2FYN | |
| SCHEMBL20209010 | 0.80 | CYP1A2 (0.54) | CYP1A2SCN5ATNFFGFR1FGFR4 | |
| SCHEMBL20203847 | 0.80 | CYP1A2 (0.59) | CYP1A2SCN5AFGFR1FGFR4 | |
| SCHEMBL26539127 | 0.79 | CYP1A2 (0.55) | CYP1A2SCN5AMKNK1MKNK2FGFR1 | |
| SCHEMBL23572493 | 0.79 | CYP1A2 (0.44) | CYP1A2SCN5A | |
| SCHEMBL20209245 | 0.78 | CYP1A2 (0.51) | CYP1A2SCN5ATNF | |
| SCHEMBL20208584 | 0.77 | MKNK1 (0.51) | CYP1A2SCN5AMKNK1MKNK2FYN | |
| SCHEMBL26462170 | 0.75 | CYP1A2 (0.46) | CYP1A2FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885MKNK1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.